KAWASAKI,Japan,Feb. 13,2025-- Fujitsu today announced the launch of theFujitsu Cloud Service Generative AI Platform. The new service,which combines data confidentiality with the ease of use of the clo
XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM).
- The company reports KRW373.0 billion in net sales,KRW166.3 billion in operating profit,and KRW142.4 billion in net income,reflecting year-over-year increases of 16.7%,41.2%,and 45.8%,respectively
NEW YORK,Feb. 13,2025-- Accropeutics Inc. (Accropeutics),a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell deat
O-RAN ALLIANCE calls for participation in the O-RAN Global PlugFest Spring 2025 with 23 hosts in 18 labs around the world
Control Center Becomes Daily Companion,Sole Source of Truth,Streamlining Management of Clarifai Operations